Danish biotech company, which raised DKK 225m (USD 36.2m) in capital in 2019 from a series of European venture funds including Novo Seeds will be changing its CEO.
Co-founder, CEO and Chief Scientific Officer Simon Glerup leaves the company, which is developing a tablet against blood clots in the heart. Now, he will function as the CSO and board member of the firm, while Andrew Hotchkiss, who has previously worked for Eli Lilly-owned biotech firm Dermira, will take on the role of CEO, according to a Wednesday press release.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.